Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell tumor post-nephrectomy—A case report
An effective and potentially less nephrotoxic chemo-mobilization regimen, using paclitaxel and cyclophosphamide (TC-CE), was administered to a patient with refractory metastatic germ-cell tumor who underwent HDCT followed by ASCT rescue after unilateral nephrectomy. Cyclophosphamide demonstrated to be a viable substitute for ifosfamide within the TI-CE regimen.
Authors
- Alwin D. R. Huitema (ORCID: https://orcid.org/0000-0003-1939-4639)
- Loek A. W. de Jong (ORCID: https://orcid.org/0000-0002-3989-8386)
- Nielka P. van Erp (ORCID: https://orcid.org/0000-0003-1553-178X)
- Ingrid M.E. Desar (ORCID: https://orcid.org/0000-0003-0945-8299)
- Minke Smits (ORCID: https://orcid.org/0000-0003-1360-7285)
- Lotte M. G. Hulskotte (ORCID: https://orcid.org/0009-0004-6948-4442)
- Joost Sijm
Institutions
- Radboud University Nijmegen (NL)
- Utrecht University (NL)
- Radboud University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Oncode Institute (NL)
- Princess Máxima Center (NL)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1007/s00280-025-04818-0
- Primary Topic
- Chemotherapy-induced organ toxicity mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00